Literature DB >> 22538716

Germline RAD51C mutations confer susceptibility to ovarian cancer.

Chey Loveday, Clare Turnbull, Elise Ruark, Rosa Maria Munoz Xicola, Emma Ramsay, Deborah Hughes, Margaret Warren-Perry, Katie Snape, Diana Eccles, D Gareth Evans, Martin Gore, Anthony Renwick, Sheila Seal, Antonis C Antoniou, Nazneen Rahman.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22538716     DOI： 10.1038/ng.2224

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


× No keyword cloud information.
  15 in total

1.  Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.

Authors:  Yonglan Zheng; Jing Zhang; Kisha Hope; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Breast Cancer Res Treat       Date:  2010-08-10       Impact factor: 4.872

Review 2.  ATM and breast cancer susceptibility.

Authors:  M Ahmed; N Rahman
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

3.  RAD51C is a susceptibility gene for ovarian cancer.

Authors:  Liisa M Pelttari; Tuomas Heikkinen; Deborah Thompson; Anne Kallioniemi; Johanna Schleutker; Kaija Holli; Carl Blomqvist; Kristiina Aittomäki; Ralf Bützow; Heli Nevanlinna
Journal:  Hum Mol Genet       Date:  2011-05-25       Impact factor: 6.150

4.  Fanconi anemia and breast cancer susceptibility meet again.

Authors:  Ephrat Levy-Lahad
Journal:  Nat Genet       Date:  2010-05       Impact factor: 38.330

5.  A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families.

Authors:  Atocha Romero; Pedro Pérez-Segura; Alicia Tosar; José Angel García-Saenz; Eduardo Díaz-Rubio; Trinidad Caldés; Miguel de la Hoya
Journal:  Breast Cancer Res Treat       Date:  2011-05-03       Impact factor: 4.872

6.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

7.  BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.

Authors:  Michelle W Wong; Cecilia Nordfors; David Mossman; Gordana Pecenpetelovska; Kelly A Avery-Kiejda; Bente Talseth-Palmer; Nikola A Bowden; Rodney J Scott
Journal:  Breast Cancer Res Treat       Date:  2011-03-16       Impact factor: 4.872

8.  Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.

Authors:  Ella R Thompson; Samantha E Boyle; Julie Johnson; Georgina L Ryland; Sarah Sawyer; David Y H Choong; Georgia Chenevix-Trench; Alison H Trainer; Geoffrey J Lindeman; Gillian Mitchell; Paul A James; Ian G Campbell
Journal:  Hum Mutat       Date:  2011-11-04       Impact factor: 4.878

9.  Germline mutations in RAD51D confer susceptibility to ovarian cancer.

Authors:  Chey Loveday; Clare Turnbull; Emma Ramsay; Deborah Hughes; Elise Ruark; Jessica R Frankum; Georgina Bowden; Bolot Kalmyrzaev; Margaret Warren-Perry; Katie Snape; Julian W Adlard; Julian Barwell; Jonathan Berg; Angela F Brady; Carole Brewer; Glen Brice; Cyril Chapman; Jackie Cook; Rosemarie Davidson; Alan Donaldson; Fiona Douglas; Lynn Greenhalgh; Alex Henderson; Louise Izatt; Ajith Kumar; Fiona Lalloo; Zosia Miedzybrodzka; Patrick J Morrison; Joan Paterson; Mary Porteous; Mark T Rogers; Susan Shanley; Lisa Walker; Diana Eccles; D Gareth Evans; Anthony Renwick; Sheila Seal; Christopher J Lord; Alan Ashworth; Jorge S Reis-Filho; Antonis C Antoniou; Nazneen Rahman
Journal:  Nat Genet       Date:  2011-08-07       Impact factor: 38.330

10.  Mutation screening of RAD51C in male breast cancer patients.

Authors:  Valentina Silvestri; Piera Rizzolo; Mario Falchetti; Ines Zanna; Giovanna Masala; Domenico Palli; Laura Ottini
Journal:  Breast Cancer Res       Date:  2011-02-08       Impact factor: 6.466
View more
  91 in total

1.  Testing times.

Authors: 
Journal:  Nat Genet       Date:  2012-04-26       Impact factor: 38.330

2.  DNA crosslinking damage and cancer - a tale of friend and foe.

Authors:  Yaling Huang; Lei Li
Journal:  Transl Cancer Res       Date:  2013-06       Impact factor: 1.241

Review 3.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

4.  Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.

Authors:  Sarah J Hill; Brennan Decker; Emma A Roberts; Neil S Horowitz; Michael G Muto; Michael J Worley; Colleen M Feltmate; Marisa R Nucci; Elizabeth M Swisher; Huy Nguyen; Chunyu Yang; Ryuji Morizane; Bose S Kochupurakkal; Khanh T Do; Panagiotis A Konstantinopoulos; Joyce F Liu; Joseph V Bonventre; Ursula A Matulonis; Geoffrey I Shapiro; Ross S Berkowitz; Christopher P Crum; Alan D D'Andrea
Journal:  Cancer Discov       Date:  2018-09-13       Impact factor: 39.397

5.  Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.

Authors:  Magdalena Koczkowska; Natalia Krawczynska; Maciej Stukan; Alina Kuzniacka; Izabela Brozek; Marcin Sniadecki; Jaroslaw Debniak; Dariusz Wydra; Wojciech Biernat; Piotr Kozlowski; Janusz Limon; Bartosz Wasag; Magdalena Ratajska
Journal:  Cancers (Basel)       Date:  2018-11-14       Impact factor: 6.639

Review 6.  Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

Authors:  Katsutoshi Oda; Michihiro Tanikawa; Kenbun Sone; Mayuyo Mori-Uchino; Yutaka Osuga; Tomoyuki Fujii
Journal:  Int J Clin Oncol       Date:  2017-05-15       Impact factor: 3.402

7.  Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.

Authors:  Na Li; Simone McInerny; Magnus Zethoven; Dane Cheasley; Belle W X Lim; Simone M Rowley; Lisa Devereux; Norah Grewal; Somayeh Ahmadloo; David Byrne; Jue Er Amanda Lee; Jason Li; Stephen B Fox; Thomas John; Yoland Antill; Kylie L Gorringe; Paul A James; Ian G Campbell
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

8.  Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer.

Authors:  Grégoire Davy; Antoine Rousselin; Nicolas Goardon; Laurent Castéra; Valentin Harter; Angelina Legros; Etienne Muller; Robin Fouillet; Baptiste Brault; Anna S Smirnova; Fréderic Lemoine; Pierre de la Grange; Marine Guillaud-Bataille; Virginie Caux-Moncoutier; Claude Houdayer; Françoise Bonnet; Cécile Blanc-Fournier; Pascaline Gaildrat; Thierry Frebourg; Alexandra Martins; Dominique Vaur; Sophie Krieger
Journal:  Eur J Hum Genet       Date:  2017-07-26       Impact factor: 4.246

9.  Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.

Authors:  Kari L Ring; Amanda S Bruegl; Brian A Allen; Eric P Elkin; Nanda Singh; Anne-Renee Hartman; Molly S Daniels; Russell R Broaddus
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

10.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

Authors:  Nadine Tung; Nancy U Lin; John Kidd; Brian A Allen; Nanda Singh; Richard J Wenstrup; Anne-Renee Hartman; Eric P Winer; Judy E Garber
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.